Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma.

glucose transporter 1 prognostic factor pulmonary pleomorphic carcinoma

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
03 Feb 2020
Historique:
received: 19 12 2019
revised: 26 01 2020
accepted: 28 01 2020
entrez: 8 2 2020
pubmed: 8 2 2020
medline: 8 2 2020
Statut: epublish

Résumé

Glucose metabolism is necessary for tumor progression, metastasis, and survival in various human cancers. Glucose transporter 1 (GLUT1), in particular, plays an important role in the mechanism of ¹⁸F-FDG (2-[¹⁸F]-fluoro-2-deoxy-d-glucose) within tumor cells. However, little is known about the clinicopathological significance of GLUT1 in patients with pulmonary pleomorphic carcinoma (PPC). Adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, poorly differentiated carcinoma, large cell carcinoma, and others were identified as epithelial components, and spindle-cell type, giant-cell type, and both spindle- and giant-cell types were identified as sarcomatous components. This study was performed to determine the prognostic impact of GLUT1 expression in PPC. Patients with surgically resected PPC (n = 104) were evaluated by immunohistochemistry analysis to detect GLUT1 expression and determine the Ki-67 labeling index using specimens of the resected tumors. GLUT1 was highly expressed in 48% (50/104) of all patients, 42% (20/48) of the patients with an adenocarcinoma component, and 53% (30/56) of the patients with a nonadenocarcinoma component. High expression of GLUT1 was significantly associated with advanced stage, vascular invasion, pleural invasion, and tumor cell proliferation as determined by Ki-67 labeling. GLUT1 expression and tumor cell proliferation were significantly correlated according to the Ki-67 labeling in all patients (Spearman's rank; r = 0.25,

Identifiants

pubmed: 32028659
pii: jcm9020413
doi: 10.3390/jcm9020413
pmc: PMC7074371
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Eur J Cancer. 2018 Sep;101:181-190
pubmed: 30077123
Cancer. 1994 Jun 15;73(12):2936-45
pubmed: 8199991
J Clin Oncol. 2010 Aug 10;28(23):3746-53
pubmed: 20625125
Cancers (Basel). 2019 Oct 24;11(11):
pubmed: 31653009
Gene. 2019 Mar 20;689:76-83
pubmed: 30552981
Hum Pathol. 2019 Feb;84:142-149
pubmed: 30300664
Lung Cancer. 2001 Oct;34(1):91-7
pubmed: 11557118
Lung Cancer. 2011 Feb;71(2):144-50
pubmed: 20646779
Anticancer Res. 2019 Jan;39(1):395-403
pubmed: 30591486

Auteurs

Hisao Imai (H)

Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Japan.

Kyoichi Kaira (K)

Department of Innovative Immune-Oncology Therapeutics, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama University Hospital, Hidaka 350-1298, Japan.

Hideki Endoh (H)

Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, Saku 385-0051, Japan.

Kazuyoshi Imaizumi (K)

Department of Respiratory Medicine, Fujita Health University, Toyoake 470-1192, Japan.

Yasuhiro Goto (Y)

Department of Respiratory Medicine, Fujita Health University, Toyoake 470-1192, Japan.

Mitsuhiro Kamiyoshihara (M)

Department of General Thoracic Surgery, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.

Takayuki Kosaka (T)

Division of thoracic surgery, Takasaki General Medical Center, Takasaki 370-0829, Japan.

Toshiki Yajima (T)

Department of Innovative Immune-Oncology Therapeutics, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.

Yoichi Ohtaki (Y)

Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.

Takashi Osaki (T)

Department of Respiratory Medicine, Shibukawa Medical Center, Shibukawa 377-0280, Japan.

Yoshihito Kogure (Y)

Department of Respiratory Medicine, Nagoya Medical Center, Nagoya 460-0001, Japan.

Shigebumi Tanaka (S)

Department of Respiratory Surgery, Isesaki Municipal Hospital, Isesaki 372-0817, Japan.

Atsushi Fujita (A)

Division of Thoracic Surgery, Gunma Prefectural Cancer Center, Ota 373-8550, Japan.

Tetsunari Oyama (T)

Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.

Koichi Minato (K)

Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Japan.

Takayuki Asao (T)

Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi 371-8511, Japan.

Ken Shirabe (K)

Department of Innovative Immune-Oncology Therapeutics, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, 371-8511, Japan.

Classifications MeSH